Guardant Health Receives FDA Emergency Use Authorization for its Guardant-19 Next Generation Sequencing-Based COVID-19 TestGlobeNewsWire • 08/24/20
Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q2 2020 - Earnings Call TranscriptSeeking Alpha • 08/07/20
First liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers, Guardant Health's Guardant360® CDx, advancing precision oncology in Asia, Middle East and Africa.PRNewsWire • 08/07/20
Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid CancersGlobeNewsWire • 08/07/20
Guardant Health Announces Collaboration with Radius Health to Develop Liquid Biopsy Companion Diagnostic for ElacestrantGlobeNewsWire • 07/30/20
Guardant Health Announces Webcast of Second Quarter Financial Results on August 6, 2020GlobeNewsWire • 07/21/20
Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion DiagnosticGlobeNewsWire • 07/08/20
Guardant Health Launches Real-World Clinical-Genomic Platform to Accelerate Precision Oncology Drug DevelopmentGlobeNewsWire • 06/23/20
Guardant Health Presents Data at AACR Virtual Annual Meeting II Showing Liquid Biopsy Highly Accurate in Detecting Early-Stage Colorectal CancerGlobeNewsWire • 06/22/20
Guardant Health Announces Full Exercise of Option and Closing of Public OfferingGlobeNewsWire • 06/08/20